Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Early Phase 1
2(40.0%)
5Total
Phase 1(3)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03421613Early Phase 1Completed

3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)

Role: lead

NCT03142178Phase 1Completed

3VM for Treatment of Chronic Osteoarthritis Knee Pain

Role: lead

NCT02197182Early Phase 1Terminated

LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study

Role: lead

NCT02332148Phase 1Unknown

Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis.

Role: lead

NCT01762670Phase 1Terminated

GoldenCareTM for the Treatment of Bacterial Vaginosis

Role: lead

All 5 trials loaded